Urothelial Bladder Cancer | Oncology Today with Dr Neil Love: Role of HER2-Directed Therapy in the Treatment of HER2-Expressing Urothelial Bladder Cancer — Part 3 of a Special 3-Part Edition

Featuring perspectives from Dr Matthew D Galsky, including the following topics:

• HER2 alterations in urothelial cancer and current targeting approaches (0:00)
• Key findings supporting the use of trastuzumab deruxtecan for patients with HER2-overexpressing cancers as part of the Phase II DESTINY-PanTumor02 study (9:39)
• Targeting of HER2 using disitamab vedotin both as a monotherapy and in combination with other treatments (14:31)
• Case: A man in his late 70s with a history of non-muscle-invasive bladder cancer who develops HER2-positive lung metastases (28:57)
• Case: A man in his late 60s who receives disitamab vedotin for HER2 IHC 2+ metastatic urothelial cancer (36:25)
• Enfortumab vedotin and pembrolizumab as first-line or neoadjuvant therapy for targeting HER2-expressing cancers (39:34)
• Future direction of HER2-targeting therapies for urothelial bladder cancer (1:02:48)

CME information and select publications